Achieving Rapid, High-Titer Expression For Next-Generation Biologics

By Laura Daley, Ph.D., Senior Director, Molecular & Cellular Biology, Catalent Biologics

Catalent’s GPEx® Lightning technology is a cutting-edge platform that enables the rapid and efficient genetic engineering of high-expressing, highly stable production cell lines. Designed to accelerate biologic drug development, this standardized and scalable system ensures consistent performance from early laboratory research to full-scale GMP bioreactor production, facilitating seamless scale-up and reducing development timelines.

With a proven track record across a wide range of protein therapeutics, GPEx® Lightning supports the generation of robust cell lines for standard monoclonal antibodies (mAbs) as well as next-generation biologics, including bispecific and multi-specific antibodies, multi-gene constructs, and other complex molecules. The technology’s optimized workflows and proprietary engineering methods enhance cell line stability and productivity, making it a reliable solution for biopharmaceutical companies seeking to streamline development while maintaining high-quality protein expression.